Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China-Product Scare Hits Home, Too (China)

This article was originally published in PharmAsia News

Executive Summary

Chinese authorities are halting the export of the toothpaste by Tian Qi Company and others making toothpaste tainted with poisonous diethylene glycol. However, China is allowing these companies to sell through its voluminous stock within China. In 2006, five people allegedly died from injections of Chinese-made gall-bladder medicine because it too contained diethylene glycol. Chinese Premier Wen Jiabao responded at the time by saying, "The pharmaceutical market is in disorder." Today China's inspection bureaucracy is overwhelmed by the expanding number of pharmaceutical and food companies in China, many of them small businesses. China also maintains much more lax standards within China than for Chinese companies producing for the export market. (Click here for more - May Require Paid Subscription

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel